Hypertension Screening and Treatment Program
Information source: Department of Veterans Affairs
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Chlorthalidone (Drug); Furosemide (Drug)
Phase: N/A
Status: Completed
Sponsored by: Department of Veterans Affairs
Summary
Hypertension is one of the most common medical problems in the United States and in the VA
health care system. It has been well-documented that hypertension can be effectively
treated. However, there remain important unresolved clinical questions in the area of
antihypertensive treatment. For example, how much is mortality affected by visit compliance,
blood pressure control and type of antihypertensive agent? Or, are some regimens associated
with more morbidity than others? Or, are there inexpensive regimens that are as effective as
more expensive regimens? The amount of data that is available from this demonstration
project (currently 6,100 patients) will help address these questions. The answers to these
questions should result in better care for veterans with hypertension.
Clinical Details
Official title: VA HYPERTENSION SCREENING AND TREATMENT PROGRAM (PILOT STUDY)
Study design: Longitudinal, Defined Population, Prospective Study
Detailed description:
Primary Hypothesis: A variety of clinical questions of major importance can be addressed
using clinical data routinely obtained in the VA Hypertension Screening and Treatment
Program. For example, treatment of mild hypertension reduces the risk of strokes and heart
attacks.
Secondary Hypothesis: Target organ damage occurs despite blood pressure control.
Intervention: Chlorthalidone, furosemide, hydrochlorothiazide, metolazone, indapamide,
amiloride, spironolactone, triamterene, atenolol, metoprolol, nadolol, pindolol, propranolol,
timolol, acebutolol, penbutolol, clonidine, guanethidine, methydopa, prazosin, guanadrel,
labetalol, reserpine, guanfacine, hydralazine, minoxidil, captopril, enalapril, lisinopril,
diltiazem, nifedipine, verapamil, nicardipine, dyazide, maxzide, pargyline, terazosin, other
anti-hypertensives.
Primary Outcomes: Blood Pressure and Target Organ Damage
Study Abstract: Hypertension is one of the most common medical problems in the United States
and in the VA health care system. It has been well-documented that hypertension can be
effectively treated. However, there remain important unresolved clinical questions in the
area of antihypertensive treatment. For example, how much is mortality affected by visit
compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens
associated with more morbidity than others? Or, are there inexpensive regimens that are as
effective as more expensive regimens? The amount of data that is available from this
demonstration project (currently 6,100 patients) will help address these questions. The
answers to these questions should result in better care for veterans with hypertension.
This demonstration project provides for central collection of a standard set of clinical data
for patients at some of the Hypertension Screening and Treatment Program clinics, thereby
setting up a national data base on the treatment of hypertension. The primary objective of
this project is to demonstrate the value of establishing this type of database. The database
is being used to estimate the average annual cost of different antihypertensive regimens, to
determine the cost-efficacy of different therapies and the least expensive effective therapy
and to address some major unanswered clinical questions that require large populations and
long-term patient care data. There are currently 13 medical centers participating.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Patients at Hypertension Screening and Treatment Program clinics
Locations and Contacts
Vamc - San Juan, Pr, San Juan, Puerto Rico
Vamc - Sepulveda, Sepulveda, California, United States
Vamc - Washington, Dc, Washington, District of Columbia, United States
Vamc - Miami, Miami, Florida, United States
Vamc - Indianapolis, Indianapolis, Indiana, United States
Vamc - Iowa City, Iowa City, Iowa, United States
Vamc - Jackson, Jackson, Mississippi, United States
Vamc - Dayton, Dayton, Ohio, United States
Vamc - Philadelphia, Philadelphia, Pennsylvania, United States
Vamc - Pittsburgh, Pittsburgh, Pennsylvania, United States
Vamc - Memphis, Memphis, Tennessee, United States
Vamc - Richmond, Richmond, Virginia, United States
Additional Information
Starting date: June 1989
Last updated: June 23, 2005
|
